Niagen Bioscience Inc
NAGE
NASDAQ·Healthcare·Biotechnology·Mkt cap $252.5M
$3.17
▲ +1.93%
P/E
15.95
Mkt Cap
$252.5M
52-Wk Range
$2.87–$10.52
52-Week Range
$2.87 - $10.52
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 66.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary NAD+ research and intellectual property
- Strong scientific advisory board and clinical validation
- Growing consumer awareness of healthy aging trends
- First-mover advantage in NAD+ therapeutic space
Bear Case
2 risks
- High volatility (beta 2.1). Larger-than-normal price swings expected.
- Premium valuation to sector peers
Growth
Stable outlook
Expansion of NAD+ clinical trial pipeline
Value
Premium valuation to sector peers
Momentum
Weak
-8.1% over 3m
Quality
Excellent
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying NAGE right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 3, 2026
AUG 4, 2026
Reported EPS of $0.01 vs $0.01 consensus (+20.1% surprise). Revenue of $29.8M vs $30.5M expected (-2.5%).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+20.1%
Revenue trend · last 8Q
—
—
—
+37%
+33%
+16%
+3%
-4%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$25.6M
$29.1M
$30.5M
$31.1M
$34.0M
$33.8M
$31.5M
$29.8M
Margins · last 8Q
Gross
—
Operating
—
Profit
3.2%
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Roth Capital · Aug 5, 2026
vs Industry
How NAGE stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.